sophoricoside and Parkinson-Disease

sophoricoside has been researched along with Parkinson-Disease* in 1 studies

Other Studies

1 other study(ies) available for sophoricoside and Parkinson-Disease

Article	Year
Oral administration of sophoricoside (SOP) inhibits neuronal damage and neuroinflammation to curb neurodegeneration in Parkinson's disease. Chemico-biological interactions, 2023, Oct-01, Volume: 384 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Administration, Oral; Animals; Disease Models, Animal; Dopaminergic Neurons; Mammals; Mice; Mice, Inbred C57BL; Microglia; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappa B; Parkinson Disease	2023

Article

Year

Oral administration of sophoricoside (SOP) inhibits neuronal damage and neuroinflammation to curb neurodegeneration in Parkinson's disease.

Chemico-biological interactions, 2023, Oct-01, Volume: 384

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Administration, Oral; Animals; Disease Models, Animal; Dopaminergic Neurons; Mammals; Mice; Mice, Inbred C57BL; Microglia; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappa B; Parkinson Disease

2023